- Home
- FGMC vs THTX Comparison
FGMC vs THTX Comparison
Compare FGMC & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGMC
- THTX
- Stock Information
- Founded
- FGMC 2023
- THTX 1993
- Country
- FGMC United States
- THTX Canada
- Employees
- FGMC N/A
- THTX N/A
- Industry
- FGMC
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- FGMC
- THTX Health Care
- Exchange
- FGMC NYSE
- THTX Nasdaq
- Market Cap
- FGMC 101.8M
- THTX 119.1M
- IPO Year
- FGMC 2025
- THTX N/A
- Fundamental
- Price
- FGMC $9.85
- THTX $3.15
- Analyst Decision
- FGMC
- THTX Hold
- Analyst Count
- FGMC 0
- THTX 1
- Target Price
- FGMC N/A
- THTX N/A
- AVG Volume (30 Days)
- FGMC 21.6K
- THTX 1.0M
- Earning Date
- FGMC 01-01-0001
- THTX 07-09-2025
- Dividend Yield
- FGMC N/A
- THTX N/A
- EPS Growth
- FGMC N/A
- THTX N/A
- EPS
- FGMC 0.08
- THTX N/A
- Revenue
- FGMC N/A
- THTX $84,378,000.00
- Revenue This Year
- FGMC N/A
- THTX N/A
- Revenue Next Year
- FGMC N/A
- THTX $15.13
- P/E Ratio
- FGMC $573.47
- THTX N/A
- Revenue Growth
- FGMC N/A
- THTX 2.19
- 52 Week Low
- FGMC $9.53
- THTX $1.12
- 52 Week High
- FGMC $9.90
- THTX $3.20
- Technical
- Relative Strength Index (RSI)
- FGMC N/A
- THTX 73.35
- Support Level
- FGMC N/A
- THTX $2.28
- Resistance Level
- FGMC N/A
- THTX $3.20
- Average True Range (ATR)
- FGMC 0.00
- THTX 0.07
- MACD
- FGMC 0.00
- THTX 0.08
- Stochastic Oscillator
- FGMC 0.00
- THTX 94.79
About FGMC FG MERGER II CORP
FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.